Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 164

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC)

Open access
Rinaldi, S, Peeters, P H M, Berrino, F, Dossus, L, Biessy, C, Olsen, A, Tjonneland, A, Overvad, K, Clavel-Chapelon, F, Boutron-Ruault, M C, Téhard, B, Nagel, G, Linseisen, J, Boeing, H, Lahmann, P H, Trichopoulou, A, Trichopoulos, D, Koliva, M, Palli, D, Panico, S, Tumino, R, Sacerdote, C, van Gils, C H, van Noord, P, Grobbee, D E, Bueno-de-Mesquita, H B, Gonzalez, C A, Agudo, A, Chirlaque, M D, Barricarte, A, Larrañaga, N, Quiros, J R, Bingham, S, Khaw, K T, Key, T, Allen, N E, Lukanova, A, Slimani, N, Saracci, R, Riboli, E, Kaaks, R·2006·Endocrine-Related Cancer

Abstract

Blood concentrations of insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) have recently been associated with breast cancer risk, notably in women who developed breast cancer at a young age. Prospective studies published so far, however, were relatively small and odds ratio (OR) estimates imprecise. We present the results of a large prospective case-control study nested within the European Prospective Investigation into Cancer and Nutrition on total IGF-I, IGFBP-3 and breast cancer risk including 1081 incident cases of invasive breast cancer and 2098 matched control subjects. Increasing IGF-I and IGFBP-3 concentrations were associated with a significant increase in breast cancer risk in women who developed breast cancer after 50 years of age (highest vs lowest quintile OR 1.38 (95% confidence interval (CI) 1.02–1.86), P = 0.01, and 1.44 (95% CI 1.04–1.98), P = 0.01, respectively), but no relationship was observed in younger women (OR = 1.03 (95% CI 0.60–1.77), P = 0.81 for IGF-I, and OR = 0.92 (95% CI 0.50–1.70), P = 0.69 for IGFBP-3). There was, however, significant heterogeneity in the relationship of breast cancer with serum IGF-I and IGFBP-3 levels depending on the time interval between blood donation and tumor diagnosis. A reduction in breast cancer risk with increasing IGF-I concentrations was observed in cases with a diagnosis of cancer less than 2 years after blood donation, (OR = 0.76 (95% CI 0.57–1.03)), while an increase in risk was observed for women with a later diagnosis (above or equal to two years after blood collection, OR = 1.51 (95% CI 1.19–1.91)). A similar pattern was observed for IGFBP-3. This study confirms previous findings for an association of serum IGF-I and IGFBP-3 concentrations with breast cancer risk, particularly for women with a later diagnosis of cancer, but it does not support the hypothesis of an involvement of IGF-I in younger women.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1677/erc.1.01150

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 164

Metadata

Authors
Rinaldi, S., Peeters, P. H. M., Berrino, F., Dossus, L., Biessy, C., Olsen, A., Tjonneland, A., Overvad, K., Clavel-Chapelon, F., Boutron-Ruault, M. C., Téhard, B., Nagel, G., Linseisen, J., Boeing, H., Lahmann, P. H., Trichopoulou, A., Trichopoulos, D., Koliva, M., Palli, D., Panico, S., Tumino, R., Sacerdote, C., van Gils, C. H., van Noord, P., Grobbee, D. E., Bueno-de-Mesquita, H. B., Gonzalez, C. A., Agudo, A., Chirlaque, M. D., Barricarte, A., Larrañaga, N., Quiros, J. R., Bingham, S., Khaw, K. T., Key, T., Allen, N. E., Lukanova, A., Slimani, N., Saracci, R., Riboli, E., & Kaaks, R.
Venue
Endocrine-Related Cancer
Published
2006-06
Volume
13
Issue
2
Pages
593-605
ISSN
  • 1351-0088 (ISSN-L)
  • 1479-6821
OpenAlex
W2164373820
Cited by
164
References
1
FWCI
11.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.